Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Idera Pharmaceuticals Delays Initiation of Phase 2 Clinical Trial of IMO-2125 in Treatment-Naïve HCV Patients
Idera Pharmaceuticals Delays Initiation of Phase 2 Clinical Trial of IMO-2125 in Treatment-Naïve HCV Patients
Idera Pharmaceuticals Delays Initiation of Phase 2 Clinical Trial of IMO-2125 in Treatment-Naïve HCV Patients
Submitted by
admin
on April 23, 2011 - 10:47am
Source:
Yahoo/BusinessWire
News Tags:
Idera Pharmaceuticals
IMO-2125
HCV
toll-like Receptor (TLR) 9 agonist
Headline:
Idera Pharmaceuticals Delays Initiation of Phase 2 Clinical Trial of IMO-2125 in Treatment-Naïve HCV Patients
Do Not Allow Advertisers to Use My Personal information
